Daniel L. Dexter

4.8k total citations · 2 hit papers
86 papers, 4.0k citations indexed

About

Daniel L. Dexter is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Daniel L. Dexter has authored 86 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Molecular Biology, 31 papers in Oncology and 22 papers in Cancer Research. Recurrent topics in Daniel L. Dexter's work include Cancer Genomics and Diagnostics (14 papers), Cancer Cells and Metastasis (11 papers) and Biochemical and Molecular Research (10 papers). Daniel L. Dexter is often cited by papers focused on Cancer Genomics and Diagnostics (14 papers), Cancer Cells and Metastasis (11 papers) and Biochemical and Molecular Research (10 papers). Daniel L. Dexter collaborates with scholars based in United States, United Kingdom and Canada. Daniel L. Dexter's co-authors include Paul Calabresi, John T. Leith, Ellen N. Spremulli, Gloria H. Heppner, J A Barbosa, Zuzana Fligiel, Beverly A. Blazar, Shih-Fong Chen, Betsy A. Dusak and Peter A. Calabresi and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

Daniel L. Dexter

85 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Heterogeneity of tumor cells from a single mouse mammary tumor.

1978 471 citations Daniel L. Dexter et al. PubMed profile →
N,N-dimethylformamide-induced alteration of cell culture characteristics and loss of tumorigenicity in cultured human colon carcinoma cells.

1979 239 citations Daniel L. Dexter et al. PubMed profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel L. Dexter United States	35	2.0k	1.4k	1.1k	497	385	86	4.0k
D J Chaplin United Kingdom	19	1.4k 0.7×	740 0.5×	1.0k 1.0×	290 0.6×	440 1.1×	33	3.0k
Marc Navre United States	31	1.9k 0.9×	1.3k 1.0×	1.0k 1.0×	349 0.7×	217 0.6×	49	3.8k
Richard E. Galardy United States	29	1.6k 0.8×	779 0.6×	1.3k 1.2×	334 0.7×	215 0.6×	67	4.0k
Bridget T. Hill United Kingdom	39	3.0k 1.5×	2.2k 1.6×	551 0.5×	555 1.1×	520 1.4×	193	5.3k
Joan M. Carboni United States	34	2.4k 1.2×	1.4k 1.0×	804 0.7×	386 0.8×	361 0.9×	75	4.0k
Dennis F. Deen United States	34	2.2k 1.1×	763 0.6×	929 0.9×	162 0.3×	453 1.2×	141	3.9k
Manfred F. Rajewsky Germany	38	2.9k 1.4×	799 0.6×	1.5k 1.4×	378 0.8×	245 0.6×	172	4.7k
Andrew I. Minchinton Canada	30	2.0k 1.0×	1.4k 1.0×	1.1k 1.0×	192 0.4×	604 1.6×	103	5.1k
Jörg Stürzebecher Germany	35	1.7k 0.8×	742 0.5×	718 0.7×	611 1.2×	187 0.5×	130	4.2k
Gabriella Zupi Italy	45	3.9k 1.9×	1.9k 1.4×	973 0.9×	169 0.3×	431 1.1×	161	5.6k

Countries citing papers authored by Daniel L. Dexter

Since Specialization

Citations

This map shows the geographic impact of Daniel L. Dexter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel L. Dexter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel L. Dexter more than expected).

Fields of papers citing papers by Daniel L. Dexter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel L. Dexter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel L. Dexter. The network helps show where Daniel L. Dexter may publish in the future.

Co-authorship network of co-authors of Daniel L. Dexter

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel L. Dexter. A scholar is included among the top collaborators of Daniel L. Dexter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel L. Dexter. Daniel L. Dexter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Hao, Desirée, Jinee Rizzo, Daniel L. Dexter, et al.. (2002). Preclinical Antitumor Activity and Pharmacokinetics of Methyl-2-Benzimidazolecarbamate (FB642). Investigational New Drugs. 20(3). 261–270. 34 indexed citations

2.

Agrawal, Sudhir, Ekambar R. Kandimalla, Yu Dong, et al.. (2001). Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides. International Journal of Oncology. 18(5). 1061–9. 10 indexed citations

3.

Weitman, Steven, G. Mangold, Daniel L. Dexter, et al.. (1999). Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft. Cancer Chemotherapy and Pharmacology. 43(5). 402–408. 16 indexed citations

4.

Frucht, Harold, et al.. (1998). Functional expression of m3 muscarinic cholinergic receptors on human colon cancer cell lines. Gastroenterology. 114. A598–A598. 1 indexed citations

5.

Zhang, Xichen, Helen M. Burt, Daniel D. Von Hoff, et al.. (1997). An investigation of the antitumour activity and biodistribution of polymeric micellar paclitaxel. Cancer Chemotherapy and Pharmacology. 40(1). 81–86. 91 indexed citations

6.

Houghton, Peter J., Pamela J. Cheshire, Janet L. Gross, et al.. (1994). Evaluation of a novel bis-naphthalimide anticancer agent, DMP 840, against human xenografts derived from adult, juvenile, and pediatric cancers. Cancer Chemotherapy and Pharmacology. 33(4). 265–272. 27 indexed citations

7.

Houghton, Peter J., Pamela J. Cheshire, Janet L. Gross, et al.. (1994). Evaluation of a novel bis-naphthalimide anticancer agent, DMP 840, against human xenografts derived from adult, juvenile, and pediatric cancers. Cancer Chemotherapy and Pharmacology. 33(4). 265–272. 1 indexed citations

8.

Dexter, Daniel L., et al.. (1993). Chemotherapy of mammary carcinomas arising in ras transgenic mice. Investigational New Drugs. 11(2-3). 161–168. 17 indexed citations

9.

Morrison, Richard S., Janet L. Gross, William F. Herblin, et al.. (1990). Basic fibroblast growth factor-like activity and receptors are expressed in a human glioma cell line.. PubMed. 50(8). 2524–9. 87 indexed citations

10.

Jiang, Jack B., et al.. (1990). Synthesis and biological evaluation of 2-styrylquinazolin-4(3H)-ones, a new class of antimitotic anticancer agents which inhibit tubulin polymerization. Journal of Medicinal Chemistry. 33(6). 1721–1728. 234 indexed citations

11.

Gross, Janet L., Richard S. Morrison, Kristi Eidsvoog, et al.. (1990). Basic fibroblast growth factor: A potential autocrine regulator of human glioma cell growth. Journal of Neuroscience Research. 27(4). 689–696. 56 indexed citations

12.

Chen, Shih-Fong, et al.. (1988). Distribution of the novel anticancer drug candidate brequinar sodium (DuP 785, NSC 368390) into normal and tumor tissues of nude mice bearing human colon carcinoma xenografts. Cancer Chemotherapy and Pharmacology. 22(3). 183–186. 12 indexed citations

13.

Hall, Roberta L. & Daniel L. Dexter. (1988). Smokeless tobacco use and attitudes toward smokeless tobacco among Native Americans and other adolescents in the northwest.. American Journal of Public Health. 78(12). 1586–1588. 16 indexed citations

14.

Chen, Shih-Fong, et al.. (1986). Mechanism of action of the novel anticancer agent 6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarbo xylic acid sodium salt (NSC 368390): inhibition of de novo pyrimidine nucleotide biosynthesis.. PubMed. 46(10). 5014–9. 128 indexed citations

15.

Dexter, Daniel L., David P. Hesson, Robert Ardecky, et al.. (1985). Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarb oxylic acid sodium salt], against experimental tumors.. PubMed. 45(11 Pt 1). 5563–8. 80 indexed citations

16.

Ghoda, Lucy, Todd M. Savarese, Daniel L. Dexter, et al.. (1984). Characterization of a defect in the pathway for converting 5‘-deoxy-5‘-methylthioadenosine to methionine in a subline of a cultured heterogeneous human colon carcinoma.. Journal of Biological Chemistry. 259(11). 6715–6719. 24 indexed citations

17.

Spremulli, Ellen N. & Daniel L. Dexter. (1984). Polar solvents: a novel class of antineoplastic agents.. Journal of Clinical Oncology. 2(3). 227–241. 89 indexed citations

18.

Leith, John T., et al.. (1983). Survival Responses of Cell Subpopulations Isolated from a Heterogeneous Human Colon Tumour after Combinations of Hyperthermia and X-irradiation. International Journal of Radiation Biology and Related Studies in Physics Chemistry and Medicine. 43(3). 303–311. 4 indexed citations

19.

Savarese, Todd M., Lucy Ghoda, Daniel L. Dexter, & Robert E. Parks. (1983). Conversion of 5'-deoxy-5'-methylthioadenosine and 5'-deoxy-5'-methylthioinosine to methionine in cultured human leukemic cells.. PubMed. 43(10). 4699–702. 21 indexed citations

20.

Heppner, G. H., et al.. (1978). Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 38(11 Pt 1). 3758–63. 231 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact